Certificate Reference
For continuity with the current catalog, this page links to laboratory documentation for a component or a closely related product. The linked certificate is a reference only and is not represented as the batch-specific COA for Tesamorelin.
Overview
Tesamorelin is a stabilized analog of human growth-hormone-releasing hormone (GHRH 1-44). It activates the pituitary GHRH receptor to increase endogenous pulsatile GH release and downstream IGF-1, making it a well-characterized research tool for the GH/IGF-1 axis and body-composition biology.
Research Reference: View compound profile on NIH PubChem
Research Focus
WHAT THIS FORMULA FEATURES
Unlike direct recombinant HGH, tesamorelin acts upstream through the GHRH receptor and preserves endogenous pituitary control. Controlled human research has shown increases in IGF-1 and selective changes in visceral adipose tissue, making GH secretion dynamics and depot-specific adipose responses especially relevant endpoints.
EXPECTED RESEARCH READOUTS
Typical endpoints include GH pulse amplitude and secretion profiles, IGF-1, GHRH-receptor signaling, visceral versus subcutaneous adipose measures, triglyceride and lipid markers, inflammatory markers, glucose handling, and downstream GH-axis feedback.
Research endpoints described above reflect published or model-based scientific observations and are not guaranteed outcomes. This product is strictly for research purposes only. Not approved for human or animal use.
Key Characteristics
MOLECULAR PROFILE
Formula: C221H366N72O67S
Weight: 5136 g/mol
CAS: 218949-48-5
PubChem CID: 16137828
Classification: Stabilized GHRH analogue
PHYSICAL PROPERTIES
Form: Lyophilized powder
Catalog strengths: 5 mg | 10 mg | 20 mg
Purity specification: ≥99% catalog specification; verify current batch COA
Storage: Store at −20°C (−4°F) for long-term storage or 4°C (39°F) for short-term storage; avoid repeated freeze-thaw cycles.
Testing: Batch documentation should be verified against the current lot before analytical use.
